期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
A preliminary study on rectal dose reduction associated with hyaluronic acid implantation in brachytherapy for prostate cancer
1
作者 Tairo Kashihara Yuka Urago +11 位作者 Hiroyuki Okamoto Mihiro Takemori Hiroki Nakayama Shohei Mikasa Tetsu Nakaichi Kotaro Iijima Takahito Chiba Junichi Kuwahara Satoshi Nakamura Weishan Chang Yoshiyuki Matsui Hiroshi Igaki 《Asian Journal of Urology》 CSCD 2024年第2期286-293,共8页
Objectives: Hydrogel spacer (HS) was developed to reduce rectal toxicities caused by radiotherapy, but has been reported to cause major adverse events. Our institute has attempted to introduce a hyaluronic acid (HA) a... Objectives: Hydrogel spacer (HS) was developed to reduce rectal toxicities caused by radiotherapy, but has been reported to cause major adverse events. Our institute has attempted to introduce a hyaluronic acid (HA) as an alternative spacer. This study aimed to compare rectal doses and geometric distributions between the HS and HA implantation in prostate cancer.Methods: HS and HA were inserted in 20 and 18 patients undergoing high-dose brachytherapy, respectively. The rectum spacer volumes injected were 10 mL and 22 mL, respectively. In the treatment planning system, 13.5 Gy was administered with common catheter positions. The rectal dose indices were assessed between the spacer groups for dosimetry evaluation. Distances between the prostate and rectum and configurations of the spacers were compared.Results: The mean doses irradiated to 0.1 and 2 mL of the rectum were 10.45 Gy and 6.71 Gy for HS, and 6.73 Gy and 4.90 Gy for HA (p<0.001). The mean minimum distances between the prostate and rectum were 1.23 cm and 1.79 cm for HS and HA, respectively (p<0.05). Geometrical configuration comparisons revealed that HA has a higher ability to expand the space than HS.Conclusion: The rectal dose reduction ability of HA is significantly greater than that of HS, suggesting its potential as a new spacer. 展开更多
关键词 BRACHYTHERAPY Hyaluronicacid HYDROGEL prostaticneoplasm RADIOTHERAPY
下载PDF
人羧肽酶A的cDNA克隆和原核表达 被引量:5
2
作者 武国军 郝晓柯 +4 位作者 白玉杰 张盈华 药立波 季少平 王吉村 《细胞与分子免疫学杂志》 CAS CSCD 1999年第3期165-166,169,共3页
目的:获得人羧肽酶A基因,为进一步构建、表达抗人精浆蛋白单链抗体/羧肽酶A融合蛋白,用于前列腺癌的抗体导向酶-前体药物疗法奠定基础。方法:从人正常肺组织中提取总RNA,经反转录PCR分离人羧肽酶A基因,并克隆入pUC19质粒中,用全自动荧... 目的:获得人羧肽酶A基因,为进一步构建、表达抗人精浆蛋白单链抗体/羧肽酶A融合蛋白,用于前列腺癌的抗体导向酶-前体药物疗法奠定基础。方法:从人正常肺组织中提取总RNA,经反转录PCR分离人羧肽酶A基因,并克隆入pUC19质粒中,用全自动荧光测序仪测定其序列。将该目的基因插入pBV220载体,并转入大肠杆菌DH5α中,经热诱导表达重组蛋白。结果:获得了人羧肽酶A基因(由1251bp组成,可编码417个氨基酸),与国外发表的人羧肽酶AcDNA序列一致。表达的重组蛋白以SDSPAGE分析,在Mr为49000左右处出现1条新生蛋白带,表达量约占菌体总蛋白的17%。结论:成功地克隆人羧肽酶A基因,为构建表达抗人精浆蛋白/羧肽酶A的双功能抗体奠定了基础。 展开更多
关键词 羧肽酶A 基因克隆 测序 前列腺肿瘤 CDNA
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部